AnaptysBio, Inc.
ANAB · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $852 | $640 | $570 | $376 |
| - Cash | $110 | $44 | $99 | $123 |
| + Debt | $15 | $346 | $16 | $16 |
| Enterprise Value | $757 | $942 | $487 | $269 |
| Revenue | $76 | $22 | $28 | $43 |
| % Growth | 242.8% | -19.8% | -35.6% | – |
| Gross Profit | $45 | -$16 | -$13 | $1 |
| % Margin | 58.8% | -69.9% | -48.3% | 1.2% |
| EBITDA | $38 | -$18 | -$21 | -$4 |
| % Margin | 50.1% | -82.6% | -74.2% | -8.8% |
| Net Income | $15 | -$39 | -$39 | -$22 |
| % Margin | 19.8% | -173.5% | -141.6% | -50.5% |
| EPS Diluted | 0.52 | -1.34 | -1.28 | -0.77 |
| % Growth | 138.8% | -4.7% | -66.2% | – |
| Operating Cash Flow | -$27 | -$40 | -$11 | -$67 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$27 | -$40 | -$11 | -$67 |